In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Test Location, By End-use (Hospitals, Laboratory), By Technology (Immunoassay, Coagulation), By Application, By Region, And Segment Forecasts, 2025 - 2

In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Test Location, By End-use (Hospitals, Laboratory), By Technology (Immunoassay, Coagulation), By Application, By Region, And Segment Forecasts, 2025 - 2030

Allergy Immunotherapy Market Growth & Trends

The global allergy immunotherapy market size is expected to reach USD 3.19 billion by 2030 registering a CAGR of 8.7%, according to a new report by Grand View Research, Inc. Rising prevalence of allergic conditions is expected to boost the market growth. According to the statistics published by the American Academy of Allergy, Asthma & Immunology (AAAAI), global prevalence of allergic rhinitis ranges from 10% to 30%. The disease affects 7.8% of the adult population in U.S. alone.

Technological advancements in the field of bioengineering and immunology have improved the composition of allergy shots given to patients for boosting the immune system. In addition, efforts to overcome the problems associated with safety, efficacy, standardization, costs, and long duration of immunotherapy is also expected to propel the market growth in the coming years. Europe occupied the largest market share in 2019 and will retain its leading position during the forecast period. However, Asia Pacific is estimated to be the fastest-growing regional market from 2020 to 2027.

Allergy Immunotherapy Market Report Highlights

• The Subcutaneous Immunotherapy (SCIT) segment dominated the market, with a revenue share of 66.4% in 2024, driven by its proven effectiveness, it has a long history of clinical success in effectively treating various allergies.
• The tablets segment dominated the market with the largest revenue share of 54.4% in 2024, driven by the increasing adoption of Sublingual Immunotherapy (SLIT) products, as they offer a convenient and non-invasive alternative to traditional allergy shots.
• Allergic rhinitis was the largest revenue-generating segment in 2024 and is estimated to maintain its dominance throughout the forecast period owing to the high disease burden across the globe
• Hospital pharmacy segment held the largest share in 2024 owing to a rise in the patient pool for treatment of allergic disorders in hospitals

Please note The report will be delivered in 2-3 business days upon order notification.